GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » ROC (Joel Greenblatt) %

Corium International (Corium International) ROC (Joel Greenblatt) % : -240.56% (As of Jun. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Corium International ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Corium International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was -240.56%.

The historical rank and industry rank for Corium International's ROC (Joel Greenblatt) % or its related term are showing as below:

CORI's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -335.695
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Corium International's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Corium International ROC (Joel Greenblatt) % Historical Data

The historical data trend for Corium International's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International ROC (Joel Greenblatt) % Chart

Corium International Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -62.82 -22.92 -169.99 -249.83 -334.59

Corium International Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -370.14 -351.26 -355.95 -460.19 -240.56

Competitive Comparison of Corium International's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Corium International's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corium International's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corium International's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Corium International's ROC (Joel Greenblatt) % falls into.



Corium International ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.165 + 1.975 + 0.41499999999999) - (12.072 + 0.157 + 0.187)
=-5.861

Working Capital(Q: Jun. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.556 + 1.686 + 0.92400000000001) - (11.379 + 0.137 + 0.119)
=-5.469

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Corium International for the quarter that ended in Jun. 2018 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2018  Q: Jun. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.084/( ( (14.19 + max(-5.861, 0)) + (15.81 + max(-5.469, 0)) )/ 2 )
=-36.084/( ( 14.19 + 15.81 )/ 2 )
=-36.084/15
=-240.56 %

Note: The EBIT data used here is four times the quarterly (Jun. 2018) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corium International  (NAS:CORI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Corium International ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Corium International's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Corium International (Corium International) Business Description

Traded in Other Exchanges
N/A
Address
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Executives
Essex Woodlands Health Ventures Fund Vii Lp 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil officer: Chief Financial Officer 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman director, 10 percent owner 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard director ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple director, officer: President & CEO 863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret officer: Chief Business Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Corium International (Corium International) Headlines

From GuruFocus